here, we demonstrate genome engineering in postnatal mice using AAV-split-cas9, a multifunctional platform customizable for genome editing, transcriptional regulation, and other previously impracticable applications of AAV-crisPr-cas9. We identify crucial parameters that impact efficacy and clinical translation of our platform, including viral biodistribution, editing efficiencies in various organs, antigenicity, immunological reactions, and physiological outcomes. these results reveal that AAV-crisPr-cas9 evokes host responses with distinct cellular and molecular signatures, but unlike alternative delivery methods, does not induce extensive cellular damage in vivo. our study provides a foundation for developing effective genome therapeutics.
tures 20, [23] [24] [25] [26] [27] , each with distinct design principles, have demonstrated that splitting Cas9 resolves its unwieldy size but often interferes with its function. Here, we fused the Cas9 N-terminal lobe with the Rhodothermus marinus N-split intein (Cas9 N ; 2.5 kb) and the C-terminal lobe with C-split intein (Cas9 C ; 2.2 kb), which shortened the coding sequences below those of all known Cas9 orthologs and liberated >2 kb in each AAV vector for additional elements. Split-Cas9 was fully active in transfected cells, targeting the endogenous genes tested at efficiencies equivalent to Cas9 FL ( Supplementary Fig. 1c,d ). Full activity from structure-guided split-intein reconstitution 26 contrasts with suboptimal activity from noncovalent heterodimerization 20, [23] [24] [25] , suggesting that scarless protein ligation preserves Cas9 structure and function. Next, we packaged Cas9 C -P2A-turboGFP and Cas9 N -U6-gRNAs into AAV serotype DJ (AAV-Cas9-gRNAs) ( Supplementary  Fig. 2a ) and applied the viruses to cultured cells. AAV-Cas9-gRNAs modified target genes in differentiated myotubes, tail-tip fibroblasts, and spermatogonial cells ( Supplementary Fig. 2b-f) , demonstrating robustness in three distinct cell types representing proliferative and terminally differentiated cell states.
delivery efficiency dictates genome-editing rate
To evaluate functionality in vivo, we next pseudotyped AAV-Cas9-gRNAs targeting Mstn to serotype 9 (AAV9-Cas9-gRNAs M3+M4 ) and injected the viruses intraperitoneally into neonatal mice (5E11 or 4E12 vector genomes, vg) (Fig. 1a) . Deep sequencing of whole tissues from injected mice revealed a range of editing frequencies (up to 10.9%) similar to those observed in cell culture ( Supplementary Figs. 1 and 2 ) and in single myofibers following an alternative delivery method of intramuscular DNA electroporation (Supplementary Fig. 3a) . Interestingly, editing frequencies exhibited intertissue bias for both on-target (Mstn) and off-target (chr16:+3906202) sites ( Supplementary Fig. 4a-c) , which correlated strongly with the concentrations of AAV9-Cas9-gRNAs per cell (vector genomes per mouse diploid genome, vg/dg) ( Fig. 1b and Supplementary Fig. 4d-f ). This dose dependency indicates that delivery efficiency dictates editing rate, and despite sufficiency in titers for infecting most cells ( Supplementary Fig. 4g,h ), higher AAV9-Cas9-gRNAs copies per cell continue to increase editing frequencies. Next, to demarcate viral biodistribution, we tracked AAV9-Cas9-gRNAs activity at single-cell resolution using the Ai9 mouse line 28 that accurately couples genomic excision of a 3× stop cassette with tdTomato fluorescence activation ( Fig. 1a and Supplementary Fig. 3b-d) . Systemic delivery of AAV9-Cas9-gRNAs TdL+TdR (5E11 or 4E12 vg), targeting sequences flanking the 3× stop cassette, generated excision-dependent tdTomato + cells in all examined organs (Fig. 1c, Supplementary Figs. 5 and 6 ). These data demonstrate that the AAV-split-Cas9 platform is functional for genome editing of multiple organs.
split-cas9 enables AAV delivery of cas9 fusion proteins
We next capitalized on the additional viral capacity of AAV-splitCas9 to incorporate transcription-activator fusion domains (Cas9 C fused to the 1.6-kb tripartite VPR 29 ) for targeted upregulation of gene expression (AAV-Cas9-VPR). We further made use of the fact that nuclease-active Cas9 programmed with truncated gRNAs can bind genomic loci without inducing DNA breaks, which allows use of a single Cas9-activator fusion protein for either gene editing or gene activation, depending on the gRNA spacer length 30, 31 . However, AAV-Cas9-VPR programmed with fulllength gRNAs targeting Mstn showed reduced endonucleolytic activity compared with AAV-Cas9 (Supplementary Fig. 7a ). In contrast, the same nuclease-active AAV-Cas9-VPR, programmed with truncated gRNAs (14-to 15-nt spacers), upregulated gene expression of the target Pd-l1 (Cd274), Fst, and Cd47 genes (up to 23-, 9-, and 2-fold, respectively; Fig. 1d and Supplementary  Fig. 7b,c) . Gene activation by AAV-Cas9-VPR-gRNAs inversely correlated with the basal expression levels of the target genes, potentially circumscribed by a bottleneck in the endogenous transcriptional machinery, a trend also observed with transfected nuclease-inactive 'dead' Cas9 FL (dCas9)-activator plasmids 29, 32 . Importantly, AAV-Cas9 FL s are unable to accommodate the VPR domain fusion. Hence, split-Cas9 enables AAV delivery of engineered Cas9 fusion proteins.
Postnatal gene activation with AAV9-cas9-VPr-grnAs
Next, we tested Cas9-mediated transcriptional regulation in vivo. Our initial comparison of samples treated with AAV9 -Cas9-VPR-gRNAs and AAV9-turboRFP (4E12 vg and 1E11 vg, respectively) against those with AAV9-turboRFP only (1E11 vg) could not be accurately analyzed amidst global transcriptome perturbations ( Supplementary Fig. 7d ), a host reaction that we describe in detail below. Hence, we focused on mice intramuscularly injected with equivalent dosages of AAV9-Cas9-VPR-gRNAs and AAV9-turboRFP, with only the gRNA spacer sequences varied to target different sets of genes. Compared with control mice injected with AAV9-Cas9-VPR-gRNAs targeting only Mstn and Fst, mice injected with AAV9-Cas9-VPRgRNAs targeting Mstn, Fst, Pd-l1, and Cd47 showed modest activation of the Pd-l1 and Cd47 genes (2.1-fold and 2.3-fold, respectively, as assessed by mRNA sequencing 2 weeks posttreatment) ( Fig. 1e and Supplementary Fig. 7e ). This result demonstrated, for the first time, postnatal transcriptional regulation with CRISPR-Cas9.
cas9 evokes cellular immune responses while AAV9 does not
The transcriptome perturbations observed alongside on-target gene activation provide a segue into our second aim, as these differentially expressed genes (>1,000 loci) were significantly enriched for a spectrum of immunological processes ( Supplementary Fig. 8 and Supplementary Table 1 ). This result places immunogenicity of AAV-CRISPR-Cas9 as a key property that destabilizes the host system, and could conceivably impact its use in vivo.
To address this imminent concern, we proceeded to dissect the immunological response to AAV9-split-Cas9, in parallel with the alternative delivery method of intramuscular DNA electroporation (encoding Cas9 FL ). Regardless of delivery method, expression of Cas9 in the adult tibialis anterior muscle ( Fig. 2a and Supplementary Fig. 9a ) induced enlargement of the draining lymph nodes with increased cell counts ( Supplementary  Fig. 9b ). In Cas9-expressing muscles, the frequencies of CD45 + hematopoietic cells were also significantly elevated ( Fig. 2b and Supplementary Fig. 9b ) and enriched around transgeneexpressing myofibers (Supplementary Fig. 9c ). Administering the same vectors without the Cas9 coding sequence did not elicit significant cellular infiltration or expansion, indicating a Cas9-driven immune response. Within the expanded CD45 + population, myeloid cells (CD11b + Gr1 − monocytes, macrophages, and/or dendritic cell subsets) and T cells (CD3 + CD4 + and CD3 + CD8 + ) were particularly enriched ( Fig. 2b and Supplementary Fig. 9d-f) . T cells orchestrate antigen-specific immune responses, with each clonal lineage expressing a unique T-cell receptor β-chain (TCR-β) CDR3 motif that mediate most of the antigen contact. The unique 'barcodes' of T-cell clonotypes allowed us to identify Cas9-responsive T cells through deep sequencing the TCR-β repertoires. We observed that Cas9 exposure skewed expansion of T-cell clonotypic subsets (Fig. 2c) , which implied antigen-specific T-cell activation and proliferation. Four TCR-β clonotypes were common to all Cas9-exposed animals (n = 4) and undetected in all unexposed animals (n = 8). Because bona fide T cells would proliferate with antigen recall, we sought to confirm antigen-specific T-cell expansion by challenging extracted lymphocytes with purified Cas9 protein. Of the four initial clonotypes, we identified one (Vβ16, CDR3: CASSLDRGQDTQYF) as a true Cas9-responsive T-cell clonotype, which proliferated according to Cas9 protein restimulation (Fig. 2d) . Hence, Cas9 activates a cellular immune 
(2) (7) response, with at least one antigen-specific T-cell clonotype common among injected mice (suggestive of a public response), and with the other infiltrating T cells largely dissimilar between individuals (private response).
cas9 evokes humoral immune responses
Cas9-specific antibodies were also elicited postexposure, as confirmed by ELISA (Supplementary Fig. 10a ). Individual mice exhibited variable titers of Cas9-specific antibodies, suggesting a largely private humoral response. To map Cas9 epitopes, serum from each animal was coincubated with M13 phage display libraries tiling the Cas9 transgene, and antibody targets were determined by Ig:phage pull down ( Fig. 2e and Supplementary Fig. 10b ). Epitope mapping showed that individual Cas9-exposed animals exhibited an antibody repertoire targeting unique residues of Cas9, but three linear epitopes were observed more than once (Fig. 2f, Supplementary Fig. 10c , and Supplementary Fig. 10d ). While speculative, future large-scale functional variant profiling could reveal more residues amenable to epitope recoding.
AAV9 evokes humoral immune responses
In contrast to Cas9, AAV9 elicited capsid-specific antibodies ( Supplementary Fig. 10e ) against epitopes that were shared among injected animals at surprisingly high degrees ( Fig. 2g and Supplementary Table 2) , reminiscent of a public response to viruses recently observed also in humans 34 . Epitope mapping provides intriguing support that AAV9 antigenicity derives from biophysical and functional aspects instead of purely sequencelevel motifs. The metastable VP1 unique and VP1/2 common regions are antigenic, suggesting their externalization from the viral interior for antigen capture. Immunodominant epitopes in VP3 are over-represented on the capsid surface ( Supplementary  Fig. 10f ). Notably, while many of these residues can be separately double-alanine mutated without disrupting viral assembly 35 , they are predominantly implicated 35 in maintaining viral blood persistency ( Supplementary Fig. 10g ) and liver-selective tropism ( Supplementary Fig. 10h ). Together, the immunodominant VP3 epitopes (372-FMIPQYGYLTLNDGSQAVG-390, 436-MNPLIDQYLY-445, and 494-TQNNNSEFAWPG-505) cover 12 out of the 18 residues associated with AAV9 hepatotropism. Hence, AAV9 elicits humoral immunity that overlaps among animals across substantial regions of the capsid protein that modulate viral biodistribution.
transcriptome signatures following AAV-crisPr-cas9 exposure
Having established that AAV-CRISPR-Cas9 activates host immunity, we next investigated the associated functional impact of activating the host immune system. We returned to the total mRNA sequencing data, and by using the DCQ algorithm 36 against reference gene expression profiles derived by the Immunological Genome Project (ImmGen), we deconvoluted the admixture transcriptomes into >200 immune cell types of the hematopoietic lineage tree (Fig. 3a, Supplementary Fig. 11 , and Supplementary Table 3 ). This deconvolution identified cell-type compositions concordant with bulk fractions quantified via FACS (Fig. 3b) , but it afforded higher inferential power for generating testable hypotheses. First, gene signatures for differentiated B cells, monocytes, and dendritic cells were over-represented in the draining lymph nodes ( Supplementary Fig. 11a ), consistent with the observed humoral response and expected physiological niche. Second, in muscles treated with AAV9-Cas9-VPR-gRNAs, gene signatures for subsets of dendritic cells and T cells were dominant (Fig. 3a) .
The presence of CD8 + T cells in Cas9-expressing tissues is particularly intriguing, because mature antigen-specific CD8 + T cells can induce tissue damage by cytolysis; however, from our data set we detected gene signatures that assigned the CD8 + lineage predominantly in the naïve or activated yet immature cell fates (Fig. 3a) . A closer look at genes encoding key cytolytic T-cell differentiation signals (for example, Il12, Ifn-α/β (Ifna and Ifnb1), Il2, Tbx21, and Eomes) and cytolytic effector proteins (e.g., Prf1, Gzmb, and Fasl) revealed that these genes were not altered at statistically significant levels 2 weeks posttreatment (Supplementary Table 1 ). This led us to examine functional readouts more sensitively by intratissue immunofluorescence and histology.
AAV-crisPr-cas9 does not evoke extensive cellular damage
Interleukin-2 (IL-2) is pivotal for cytolytic T-cell differentiation 37 . Downstream, perforin (Prf1) is the essential pore-forming protein released by cytolytic T lymphocytes and natural killer (NK) cells to destroy target cells. In line with mRNA sequencing, immunofluorescence indicated basal IL-2 and perforin protein levels within muscles treated with AAV9-Cas9-VPR-gRNAs, except for in sparse interstitial areas that corresponded to the highest density of cellular infiltrates ( Fig. 3c and Supplementary Fig. 12 ).
The unremarkable perforin levels suggested minimal downstream cytolysis. To quantitatively assess cellular damage, we quantified the fraction of centrally nucleated myofibers within muscle histological sections, a physiological measure indicative of myofiber degeneration and repair. Through this assay, we did not observe significant muscle cell damage and repair responses at 2 weeks after administration of AAV9-Cas9-VPR-gRNAs (Fig. 3d) . As positive controls for our assays, we examined muscles electroporated with DNA encoding Cas9 FL . In contrast, IL-2 and perforin levels were both strongly increased in muscles 2 weeks after electroporation of Cas9-encoding DNA, and significant myofiber degeneration-repair was observed (Supplementary Figs. 13 and 14a) . These observations following DNA electroporation could not simply be attributed to physical disruptions, because transgene-induced intramuscular CD45 + cellular infiltration, IgG and IgM antibody levels, IL-2 and perforin levels, and myofiber degenerationrepair ( Supplementary Figs. 13 and 14a-d) were significantly elevated over vehicle-electroporated control mice and could be partially reduced by immunosuppression (FK506). Hence, our assays, which are adequately sensitive for detecting the extensive myofiber cytolysis evoked by electroporation of Cas9-encoding DNA, did not indicate significant myofiber damage and replacement after treatment with AAV9-Cas9-VPR-gRNAs.
discussion
The use of CRISPR-Cas9 for research purposes and its and eventual clinical implementation require comprehensive evaluation of its in vivo profile, including its potential to evoke deleterious host responses. Delivery methods such as DNA electroporation and adenoviruses 38 cause severe inflammation and immunological reactions. Immunosuppression could arguably mitigate some of these detrimental consequences, but nonetheless is still associated with well-appreciated side effects ( Supplementary  Fig. 14e) . Thus, more immunologically inert delivery vectors are particularly attractive. Precedents of immune evasion or tolerance induction by viruses have been documented in natural and experimental settings 15, 39, 40 and have fuelled ongoing efforts toward understanding and reducing the risk profiles of therapeutic vectors. Here, we contribute by directly interrogating the in vivo profile of AAV-CRISPR-Cas9, specifically that of our platform that allows flexible incorporation of function-conferring domain fusions that AAV-Cas9 FL s cannot accommodate in their current forms [7] [8] [9] [10] [11] [12] [13] [14] (Supplementary Note). We established on multiple fronts that AAV-CRISPR-Cas9 activated the immune system but had difficulty detecting muscle cell damage and repair responses with adequately sensitive assays in the timeframe of our experiments. We cannot rule out that immunological cytotoxicity could be tissue context specific, but this is unlikely to affect our conclusion because prior reports suggest that the muscle is more susceptible to cytolytic responses than are organs such as the liver 15 . Another caveat is in our use of wild-type mice for platform characterization, animals with immunological features that may differ in important ways from those of human subjects, especially in the inflammatory and procytotoxic disease contexts where AAV-CRISPR-Cas9 therapeutics might most readily be employed 41 . Interestingly, prior reports have shown that delivery of other transgenes with AAV also activates CD8 + T cells lacking full functionality, with these transgene-specific CD8 + T cells exhibiting impaired cytolytic activity 42 or cell viability 43 .
npg
It is here that further investigation toward bridging these two implications of our system-immune activation and undetected cellular damage-could reveal elements that may illuminate ways to further minimize its immunogenicity. In addition, whether the host immune response to AAV-CRISPR-Cas9 may impact other aspects of its therapeutic implementation, such as the effects toward on-and off-target gene modification and activity, remains an important topic for future investigation. In subsequent studies, the Cas9-reponsive T-cell clonotype identified here could serve as a distinctive biomarker for Cas9-specific immunity. On a parallel front, additional targeted engineering of AAV-CRISPR-Cas9 could be highly fruitful in defusing unintended side effects that remain prominent, bringing us toward a genome manipulation tool that is efficacious on target and inert otherwise. Cellular and molecular dissection of the host responses evoked by AAV-CRISPR-Cas9, as reported here, should aid in such efforts. online methods Constructs and sequences. U6-driven gRNA plasmids were constructed as described 1 . AAV plasmid backbone was derived from pZac2.1-CASI-EGFP-RGB, a gift from Luk Vandenberghe (Schepens Eye Research Institute and Massachusetts Eye and Ear Infirmary). Minicircles parental plasmids were cloned in ZYCY10P3S2T, and minicircles were generated as described 44 . AAV plasmids were cloned in Stbl3 (Life Technologies C7373-03). All other plasmids were cloned in DH5α (NEB C2987H). Protein transgenes were expressed from ubiquitous hybrid promoters: SMVP promoter (generated by fusing SV40enhancer-CMV-promoter-chimeric intron), CASI promoter 45 , or CAG promoter 46 . SMVP plasmid was derived from pMAXGFP (Lonza). pCAG-GFP was a gift from Connie Cepko (Harvard Medical School, Addgene plasmid no. 11150). pAAV-CMV-HI-eGFP-Cre-WPRE-SV40pA was obtained from the University of Pennsylvania Vector Core. Sequences of gRNA spacers, genotyping primers, qPCR probes and primers are stated in Supplementary Table 4 . Sequences of split-Cas9 are stated in Supplementary Sequence.
AAV packaging and purification. AAVs were packaged via the triple-transfection method 47, 48 . HEK293 cells (Cell Biolabs AAV-100 or Agilent 240073) were plated in growth media consisting of DMEM + glutaMAX + pyruvate + 10% fetal bovine serum (FBS) (Life Technologies) supplemented with 1× MEM nonessential amino acids (Gibco). Confluency at transfection was between 70% and 90%. Media was replaced with fresh prewarmed growth media before transfection. For each 15-cm dish, 20 µg of pHelper (Cell Biolabs), 10 µg of pRepCap (encoding capsid proteins for AAV-DJ (Cell Biolabs) or AAV9 (UPenn Vector Core)), and 10 µg of pAAV were mixed in 500 µl of DMEM, and 200 µg of PEI 'MAX' (Polysciences) (40 kDa, 1 mg/ml in H 2 O, pH 7.1) added for PEI:DNA mass ratio of 5:1. The mixture was incubated for 15 min and transferred dropwise to the cell media. For large-scale AAV production, HYPERFlask 'M' (Corning) was used, and the transfection mixture consisted of 200 µg of pHelper, 100 µg of pRepCap, 100 µg of pAAV, and 2 mg of PEIMAX. The day after transfection, media was changed to DMEM + glutamax + pyruvate + 2% FBS. Cells were harvested 48-72 h after transfection by scrapping or dissociation with 1× PBS (pH7.2) + 5 mM EDTA, and they were pelleted at 1,500 g for 12 min. Cell pellets were resuspended in 1-5 ml of lysis buffer (Tris HCl pH 7.5 + 2 mM MgCl + 150 mM NaCl), and freeze-thawed 3 times between dry-ice-ethanol bath and 37 °C water bath. Cell debris was clarified via 4,000 g for 5 min, and the supernatant was collected. Downstream processing differed depending on applications. For preparation of AAV-containing lysates, the collected supernatant was treated with 50 U/ml of Benzonase (Sigma-Aldrich) and 1 U/ml of Riboshredder (Epicentre) for 30 min at 37 °C to remove unpackaged nucleic acids, filtered through a 0.45 µm PVDF filter (Millipore), and used directly on cells or stored at −80 °C.
For purification of AAV via chloroform-ammonium sulfate precipitation, 0.10 volume of chloroform and NaCl (1 M final concentration) was added to the lysate and shaken vigorously. After centrifugation, the supernatant was incubated with PEG-8000 (10% final w/v) on ice for ≥1 h or overnight. PEG-precipitated virions were centrifuged (4,000g, 30 min, 4 °C), and resuspended in 50 mM HEPES buffer (pH 8). 50 U/ml of benzonase (Sigma-Aldrich) and 1 U/ml of Riboshredder (Epicentre) were added and incubated for 30 min at 37 °C. An equal volume of chloroform was then added, and the mixture was vigorously vortexed. After centrifugation, the aqueous phase was collected and residual chloroform evaporated for 30 min. Ammonium sulfate precipitation of AAVs was performed with a 0.5 M to 2 M cutoff. AAVs were then resuspended and dialyzed in 1× PBS + 35 mM NaCl, quantified for viral titers, and stored in −80 °C.
All experiments with purified AAVs used the iodixanol density gradient ultracentrifugation purification method 47, 48 unless otherwise stated. The collected AAV supernatant was first treated with 50 U/ml benzonase and 1 U/ml Riboshredder for 30 min at 37 °C. After incubation, the lysate was concentrated to <3 ml by ultrafiltration with Amicon Ultra-15 (50 kDa MWCO; Millipore) and loaded on top of a discontinuous density gradient consisting of 2 ml each of 15%, 25%, 40%, and 60% Optiprep (Sigma-Aldrich) in an 11.2 ml Optiseal polypropylene tube (Beckman-Coulter). The tubes were ultracentrifuged at 58,000 r.p.m. at 18 °C for 1.5 h on an NVT65 rotor. The 40% fraction was extracted and dialyzed with 1× PBS (pH 7.2) supplemented with 35 mM NaCl using Amicon Ultra-15 (50 kDa or 100 kDa MWCO; Millipore). The purified AAVs were quantified for viral titers and stored in −80 °C. AAV2/9-CMV-HI-eGFP-Cre-WPRE-SV40 (Lot V4565MI-R), AAV2/9-CB7-CI-eGFP-WPRE-rBG (lot CS0516(293)), AAV2/9-CB7-CI-mCherry-WPRE-rBG (lot V4571MI-R), and AAV2/9-CMV-turboRFP-WPRE-rBG (lot V4528MI-R-DL) were obtained from the University of Pennsylvania Vector Core.
AAV titers (vector genomes) were quantified via hydrolysisprobe qPCR 49 against standard curves generated from linearized parental AAV plasmids.
Cell culture transfection and transduction. All cells were incubated at 37 °C and 5% CO 2 .
C2C12 cells were obtained from the American Tissue Collection Center (ATCC, Manassas, VA) and grown in growth media (DMEM + glutaMAX + 10% FBS). Cells were split with TypLE Express (Invitrogen) every 2-3 d and before reaching 80% confluency to prevent terminal differentiation. Passage number was kept below 15. For transfection of C2C12 myoblasts, 10 5 cells were plated per well in a 24-well plate in 500 µl of growth media. The following day, fresh media was replaced, and 800 ng of total plasmid DNA was transfected with 2.4 µl of Lipofectamine 2000 (Life Technologies). 1:1 mass ratio of vectors encoding Cas9:gRNA(s) was used. Media was replaced with differentiation media (DMEM + glutaMAX + 2% donor horse serum) 1 and 3 d postlipofection.
For differentiation of C2C12 into myotubes, 2 × 10 4 cells were plated per well in a 96-well plate in 100 µl of growth media. At confluency, 1-2 d after plating, media was replaced with fresh differentiation media (DMEM + glutaMAX + 2% donor horse serum) and further incubated for 4 d. Fresh differentiation media was replaced before transduction with AAVs. Culture media was replaced with fresh differentiation media 1d after transduction, and cells were incubated for stated durations.
The 3× stop-tdTomato reporter cell line was derived from tail-tip fibroblasts of Ai9 (ref. 28 ) mouse (JAX No. 007905) and immortalized with lentiviruses encoding the large SV40 T antigen (GenTarget Inc., LVP016-Puro). Cells were cultured in DMEM + pyruvate + glutaMAX + 10% FBS. Lipofectamine 2000 (Life Technologies) was used for transfection of plasmids, and images npg were taken 5 d after transfection. For transduction with AAVs, cells were plated at 2 × 10 4 per well in a 96-well plate in 100 µl of growth media. AAV-containing lysates or purified AAVs were applied at confluency of 70-90%. Culture media was replaced with fresh growth media the next day, and cells were incubated for stated durations.
The GC-1 spg mouse spermatogonial cell line (CRL-2053) was obtained from ATCC. Cells were cultured and transduced similarly to the 3× stop-tdTomato cell line with a Cas9 N : Cas9 C of 1:1.
Cell lines were not tested for mycoplasma contamination after commercial purchase or primary isolation. Standard sample sizes were chosen for all experiments. Exact sample sizes for experiments are stated in figure legends and text. Statistical methods were not used for predetermination of power. All animals were randomly allocated to treatment and control groups and handled equally.
Animals
In vivo electroporation. Animals were anesthetized using isoflurane and injected with 50 µl of 2 mg/ml hyaluronidase (SigmaAldrich, H4272) in the tibialis anterior muscle. After 1 h, plasmids in vehicle (10 mM Tris-HCl, pH 8.0) were injected into the muscle, followed by electroporation 50 (10 pulses of 20 ms at 100 V/cm with 100 ms intervals) using an ECM 830 Electro Square Porator (BTX Harvard Apparatus) and a two-needle array.
For Ai9 reporter activation, 30 µg of pSMVP-SpCas9 FL , 60 µg total of pCRII-U6-gRNA, and 15 µg of pCAG-GFP were used for CRISPR-Cas9 injections; 30 µg of pSMVP-Cre and 15 µg of pCAG-GFP were used for Cre injections; and 30 µg of pSMVPSpCas9 FL and 15 µg of pCAG-GFP were used for no-gRNA control injections. FK506 (Sigma-Aldrich, F4679) was administered daily at 5 mg/kg (body weight), commencing 1 d before electroporation.
For C57BL/6 gene-targeting, 30 µg of vectors encoding SpCas9 FL (pSMVP-SpCas9 or minicircle-SMVP-SpCas9), 30 µg total of pCRII-U6-gRNA, and 15 µg of pCAG-GFP were used. With cotranslating P2A-turboGFP, pCAG-GFP was omitted, and 30 µg pSMVP-SpCas9-P2A-turboGFP and 30 µg total of pCRII-U6-gRNA were used.
For immunogenicity comparison to AAV-split-Cas9, both tibialis anterior muscles of 11-week-old male C57BL/6 mice were each electroporated with 30 µg of pSMVP-Cas9 FL . Control mice were electroporated with 30 µg of plasmid vector control (consisting of the same plasmid with Cas9 coding sequence removed) per muscle. Vehicle electroporations were similarly performed. Animals were euthanized via CO 2 asphyxia and cervical dislocation 2 weeks after treatment.
Single myofiber isolation. Mice were euthanized via CO 2 asphyxia and cervical dislocation 10 d after in vivo electroporation. Single myofibers were each placed in 10 µl of QuickExtract DNA Extraction Solution and heated at 65 °C for 15 min and 95 °C for 10 min. For genotyping, the entire lysate was used in a 100 µl PCR reaction and thermocycled for 30-35 cycles because of low genomic copy numbers.
Bulk tissues were each placed in 100 µl of QuickExtract DNA Extraction Solution and heated at 65 °C for 15 min and 95 °C for 10 min. 0.5 µl of lysate was used per 25 µl PCR reaction and thermocycled for 25 cycles.
For barcoding for deep sequencing, 1 µl of each unpurified PCR reaction was added to 20 µl of barcoding PCR reaction and thermocycled (95 °C for 3 min; and 10 cycles of: 95 °C for 10 s and 72 °C for 65 s). Amplicons were pooled, the whole sequencing library purified with self-made SPRI beads (9% PEG final concentration), and sequenced on a Miseq (Illumina) for 2 × 251 cycles. FASTQ were analyzed with BLAT (with parameters -t=dna -q=dna -tileSize=11 -stepSize=5 -oneOff=1 -repMatch=10000000 -minMatch=4 -minIdentity=90 -maxGap=3 -noHead) and postalignment analyses performed with MATLAB (MathWorks). Alignments due to primer dimers were excluded by filtering off sequence alignments that did not extend >2 bp into the loci from the locus-specific primers. To minimize the impact of sequencing errors, conservative variant calling was performed by ignoring base substitutions and calling only variants that overlapped with a ±30 bp window from the designated Cas9-gRNA cut sites. Negative controls were equally analyzed for baseline sequencing error rates, against which statistical tests were performed.
Off-target sites for Mstn gRNAs were predicted using the online CRISPR Design Tool 51 (http://crispr.mit.edu/). Off-target sites were ranked by number of mismatches to the on-target sequence, and deep sequencing was performed on top hits. Sequencing reads were analyzed equally between experimental samples (AAV9-Cas9-gRNAs M3+M4 ) and control samples (AAV9-Cas9-gRNAs TdL+TdR ) using BLAT. Variant calls were performed for insertions and deletions that laid within a ±15 bp window from potential off-target cut sites.
Quantitative reverse-transcription PCR (qRT-PCR) for gene expression. Cells were processed with Taqman Cells-to-Ct kits (Thermo Fisher Scientific No. 4399002) as per manufacturer's instructions, with the modification that each qRT-PCR reaction was scaled down to 25 µl. Taqman hydrolysis probes (Thermo Fisher Scientific) used: Pd-l1 (Mm00452054_m1), Fst (Mm00514982_m1), Cd47 (Mm00495011_m1), and house-keeping gene Abl1 (Mm00802029_m1). Gene expression from targeted genes was normalized to that of Abl1 (∆Ct). For cell culture experiments, fold-changes were calculated against AAV-Cas9 C -VPR-only controls (no-gRNA) (2 −∆∆Ct ). Basal gene expression percentiles for C2C12 myotubes and GC-1 spermatogonial cells (type B spermatogonia) were retrieved from the Gene Expression Omnibus (GEO) repository (GDS2412 and GDS2390, respectively).
Total RNA from skeletal muscle tissues was extracted via TRIzol. Reverse transcription was conducted with High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems #4368814), and 5 µl of each reaction was used for qRT-PCR in 1× FastStart Essential DNA Probes Master (Roche No. 06402682001). Gene expression from targeted genes was normalized to that of Abl1 (∆Ct), and fold-changes were calculated against AAV9-turboRFP-only controls (2 −∆∆Ct ).
AAV administration in mice.
All AAV experiments in vivo were conducted in a randomized and double-blind fashion. The allocation code was unblinded only after analyses were completed. Injections used AAV9-Cas9 N -gRNAs:AAV9-Cas9 C -P2A-turboGFP and AAV9-Cas9 N -gRNAs:AAV9-Cas9 C -VPR ratios of 1:1.
3-d-old neonates were each intraperitoneally injected with 4E12, 5E11, or 2.5E11 vector genomes (vg) of total AAV9. Vector volumes were kept at 100 µl. Animals were euthanized via CO 2 asphyxia and cervical dislocation 3 weeks following injections. For AAV9-GFP and AAV9-mCherry cotransduction experiments, animals were euthanized 9 d after injection. For qPCR and deep sequencing of whole tissues, samples were taken from the heart body wall, liver, gastrocnemius muscle, olfactory bulb, ovary, testis, and diaphragm.
AAV9-Cas9-VPR-gRNAs were intramuscularly injected at Cas9 N -gRNAs:Cas9 C -VPR ratio of 1:1, at a total of 4E12 vg. To demarcate transduced tissues, 1 × 10 11 of AAV9-turboRFP was coadministered in the same mix. Control mice were injected with 1 × 10 11 of AAV9-turboRFP only, with the final injection mix at the same volume. Animals were euthanized via CO 2 asphyxia and cervical dislocation 2 weeks after AAV9-Cas9-VPRgRNA injection.
For determining AAV-and Cas9-specific immune responses, both tibialis anterior muscles of 11-week-old male C57BL/6 mice were injected with AAV9-Cas9 N and AAV9-Cas9 C (2 × 10 12 vg each). For control mice, 4 × 10 12 of AAV9 vector control (consisting of the same AAV genome with the Cas9 coding sequence removed) was injected per muscle. Vehicle injections were similarly performed. Animals were euthanized via CO 2 asphyxia and cervical dislocation 2 weeks after treatment.
Quantitative PCR (qPCR) for AAV genomic copies in tissues.
Each qPCR reaction consists of 1× FastStart Essential DNA Probes Master (Roche No. 06402682001), 100 nM of each hydrolysis probe (against the AAV ITR and the mouse Acvr2b locus), 340 nM of AAV ITR reverse primer, 100 nM each for all other forward and reverse primers, and 2.5 µl of input tissue lysate. A mastermix was first constituted before splitting 22.5 µl into each well, after which tissue lysates were added. Thermocycling conditions were: 95 °C, 15 min and 40 cycles of 95 °C, 1 min; 60 °C, 1 min. FAM and HEX fluorescence were taken every cycle. AAV genomic copies per mouse diploid genome were calculated against standard curves. For each tissue sample, two repeated samplings were performed for qPCR and deep sequencing, all on separate days, and the means plotted with s.e.m. qPCR false-positive rates were calculated similarly from two vehicle-injected negative control mice, against which statistical tests were performed. 
Cas9 restimulation and TCR-b repertoire sequencing.
Lymphocytes were isolated from both inguinal lymph nodes and one popliteal lymph node per bilaterally injected mouse. Lymph nodes were cut and incubated for 30 min in RPMI + 1 mg/ml collagenase at room temperature (RT). Lymphocytes were released by meshing through 70 µm nylon sieves, washed twice with 1× PBS + 5 mM EDTA, and resuspended in 500 µl of growth media (RPMI 1640 + 10% FBS + 1× Pen-Strep-AmphoB + 50 µM 2-βME). Cell counting was performed on a Countess device (Life Technologies). For Cas9 restimulation experiments, 2.5 µg of recombinant Cas9 (NEB) was incubated with >10 6 cells in 500 µl of growth media for 3 d. Experiments were conducted in parallel with wells containing cells without restimulation (i.e., without Cas9 protein). Cellular RNA was extracted using QIAshredder and RNeasy micro (Qiagen). Reverse transcription was performed with SMARTscribe (Clontech), using SMARTNNN template-switching adaptor as described 52 . KAPA HiFi polymerase was used for PCR. Individual RNA molecules were counted based on Unique Molecular Identifiers using MIGEC 53 and aligned with MIXCR 54 , and postanalysis was performed with MATLAB (MathWorks). Morisita-Horn indices per exposure condition were calculated by pairwise comparisons among four mice (two animals from electroporation data set and two animals from AAV data set).
ELISA.
A modified protocol adapted from Wang et al., 2015 (ref. 38) was used. Briefly, recombinant SpCas9 protein (PNA Bio, cat. no. CP01) was diluted in 1× coating buffer (KPL), and 0.5 µg was used to coat each well of 96-well Nunc MaxiSorp Plates (Thermo Scientific) overnight at 4 °C. Plates were washed three times for 5 min with 1× wash buffer (KPL) and blocked with 1% BSA Blocking Solution (KPL) for 1 h at RT. Standard curves were generated using a mouse monoclonal antibody against SpCas9 (Epigentek, clone 7A9, cat. no. A-9000-100) with final concentrations of 0, 1, 2.5, 5, 10, 25, 50, and 100 ng ml −1 and in triplicates. Serum samples were added at 1:40 dilution, and plates were incubated for 5 h at 4 °C with shaking. Wells were washed three times for 5 min, and 100 µl of HRP-labeled goat anti-mouse IgG1 (Santa Cruz; diluted 1:4,000 in 1% BSA Blocking Solution) was added to each. After incubating for 1 h at RT, wells were washed four times for 5 min, and 100 µl of ABTS ELISA HRP Substrate (KPL) was added to each. Optical density (OD) at 410 nm was measured using a plate reader (BioTek).
Fluorescent immunoassay.
To determine antibody specificity and class switching, serum levels of AAV9-specific IgM, IgG, and IgG2a from AAV9-treated mice were compared to those from vehicle-injected control mice. AAV9 viruses (1E9 vg) were coated on each well of a 96-well PVDF MaxiSorp plate for 1 h in 1× TBST, followed by 1 h of blocking in 1× TBST + 3% BSA. After three washes with 1× TBST, 1:100 diluted mouse serum was applied at 25 µl per well, for 1 h. After three washes with 1× TBST, 1:200 diluted anti-mouse secondary antibodies were added (goat anti-mouse IgG-CF633 (Biotium 20120), goat anti-mouse IgG2a-CF594 (Biotium 20259), and goat anti-mouse IgM-Dy550 (Pierce PISA510151)), and incubated for 1 h. Wells were then washed five times with 1× TBST, and fluorescence readings in 100 µl of 1× TBS were taken via a plate reader. All steps were conducted at RT. To account for autofluorescence from sera, fluorescence readings were normalized against that from wells treated similarly except for the exclusion of secondary antibodies.
Epitope mapping by M13 phage display. M13KE genome was amplified by PCR, with one end terminating with the pIII peptidase cleavage signal and the other end terminating with a 4× Gly linker followed by the mature pIII. Cas9 and AAV9 VP1 capsid coding sequence PCR products were each randomly fragmented with NEBNext dsDNA Fragmentase until about 50-300 bp. Purified fragments were treated with NEBNext End-Repair Module. After DNA purification, fragments were blunt-ligated into the M13KE PCR product overnight at 16 °C. The entire ligation reaction was purified and transformed into ER2738 (Lucigen) at 200 ng per 25 µl of bacteria with electroporation conditions of 10 µF, 600 Ω, and 1.8 kV. After 30 min recovery in SOC media, the culture was amplified by combining with 20 ml of early-log ER2738 culture. After 4 h, the culture supernatant was collected and incubated to a final concentration of 3.33% PEG-8000 and 417 mM of NaCl overnight at 4 °C. M13 phage was pelleted and resuspended in 2 ml of TBS. Phage titers were determined by LB/IPTG/X-gal blue-white plague counting, averaging >1 ×10 11 pfu/µl. For Ig:phage pulldown, 20 µl of each phage library was incubated with 5 µl of mouse serum or titrated amount of purified antibody controls (7A9 (Novus Bio), Guide-IT (Clontech), bG15 (Santa Cruz), bS18 (Santa Cruz), bD20 (Santa Cruz), and nonbinding mouse IgG isotype control (Santa Cruz)) and made up to 50 µl with TBST for 1 h at RT. For each reaction, 25 µl of Protein A/G magnetic beads (Millipore PureProteome) was first washed twice with TBST, resuspended to 10 µl, and added to the reaction for additional 30 min incubation. The beads were then washed five times with TBST, and captured Ig:phage was eluted with 100 µl of 200 mM glycine-HCl, pH 2.2, 1 mg/ml BSA for 8 min. The eluant was neutralized with 15 µl of 1 M Tris-HCl, pH 8.5. 5 µl of captured phage display eluant was used per PCR reaction, with 20 cycles of spacer amplification and 10 cycles of barcoding, and it was sequenced on a Miseq (Illumina). Each serum sample was processed for technical replication on separate days. Differential binding of phage was determined using DESeq2 (ref. 55) in R 56 , with all Cas9-unexposed (n = 16 animals) or AAVunexposed (n = 16 animals) samples as appropriate controls for nonspecific binding. Alignments and further analyses were performed with MATLAB (MathWorks). Visualization of epitopes on Cas9 (PBD ID: 4CMP, chain A) and AAV9 VP3 (PBD ID: 3UX1) structures was conducted with Pymol. Phenotypic data of doublealanine AAV9 mutants were obtained from ref. 35 , with mutant viral blood persistency calculated as the difference in blood viral levels 72 h and 10 min postinjection (both normalized to that of wildtype AAV9, with 0 denoting wildtype phenotype and negative values denoting loss of blood persistency). Mutant tropism was represented by 'Phenotypic Difference' values as described 35 . Solvent-accessibility surface area (sasa) ratios for AAV9 capsid (PDB ID: 3UX1; ref. 57) were first calculated as described 58 , and the final sasa ratio per residue calculated as the mean from a ±5 bp sliding window centered on the residue.
Total mRNA sequencing. 1 µg of TRIzol-extracted RNA from muscle tissues or draining lymph node tissues was enriched for polyAtailed mRNA and processed with NEBNext Ultra Directional RNA Library Prep Kit (New England BioLabs), followed by sequencing on a NextSeq sequencer (Illumina), giving ~30 million reads per sample. Reads were aligned to the mm10 reference genome and FPKM quantified with the Cufflinks workflow 59 , with differential expression tested with Cuffdiff 60 . GO-terms network was visualized with ClueGO 61 Cytoscape 62 plug-in. Immune cell reference transcriptomes were downloaded from the ImmGen database. DCQ deconvolution was conducted as described 36 in R 56 .
Immunostained slides were mounted with mounting media containing DAPI (Vector Laboratories, H1500).
Western blot. Muscles were harvested 2 weeks after AAV injections or plasmid electroporation. ~10 mm 3 tissue clippings were flash frozen in liquid nitrogen, followed by lysis in 300-500 µl of T-PER Tissue Protein Extraction Solution (Thermo Scientific) supplemented with 1× Complete Protease Inhibitor (Roche) and homogenized in gentleMACS M tubes (Miltenyi Biotec). 10-15 µl of each tissue lysate was run on 8% Bolt Bis-Tris Plus gels (Life Technologies) in 1× Bolt MOPS SDS running buffer at 165 V for 50 min. Protein transfer was performed with iBlot (Life Technologies) onto PVDF membranes, using program 3 for 13 min. Western blots were conducted with 1:200 of anti-Cas9 Guide-IT polyclonal antibody (Clontech 632607), 1:400 of anti-Gapdh polyclonal antibody (Santa Cruz sc-25778), and 1:2,500 of antirabbit IgG-HRP secondary antibody (Santa Cruz sc-2004), using an iBind device (Life Technologies). Stained membranes were developed with SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific) and imaged on Chemidoc MP (Bio-Rad). Band intensities were quantified with ImageJ (NIH).
Immunosuppression. FK506 was dissolved in 100% DMSO, and the stock solution was further diluted 1:100 in vehicle for final concentrations of 1% DMSO, 10% Cremophor (Sigma-Aldrich, C5135), and 1× PBS. Mice were injected daily with 5 mg/kg (body weight) of FK506, with the first injection commencing 1 d before in vivo electroporation.
For Cas9-gRNAs-injected muscles, a mix of 30 µg of minicircle-SMVP-Cas9, 15 µg of pCAG-GFP, and 30 µg total of pCRII-U6-gRNA plasmids was injected. 30 µg of minicircle-SMVP-Cas9 was injected for Cas9-only injections, 30 µg of pCRII-U6-gRNA plasmids for gRNAs-only injections, 15 µg of pCAG-GFP for GFP-only injections. Four mice were injected per condition.
For body weight measurements, 2-month-old mice were injected with 5 mg/kg/d of FK506 or vehicle for 2 weeks. Three male C57BL/6 mice were injected per condition.
Imaging and analyses. Confocal images were taken using a Zeiss LSM780 inverted microscope. For live-cell imaging, each image consists of 3× z-stacks (7 µm intervals) and 2 × 2 tiles. For muscle sections, 3× z-stacks (7 µm intervals) were used. For liver and heart sections, 4× z-stacks (10 µm intervals) were used. Tiling was used to image entire samples, followed by stitching. Stacked fluorescence images were projected by maximum intensity with Zen 2011 (Carl Zeiss).
Epifluorescence images were taken with an Axio Observer D1 (Carl Zeiss) or Axio Observer Z1 (Carl Zeiss).
For cotransduction analysis after AAV9-GFP and AAV9-mCherry administration, pixels that contained both GFP and mCherry fluorescence intensities above the background thresholds were identified, and the lower intensity values from either channel were used to populate a merged image. All other pixels in the merged image were set to null.
Centrally nucleated myofibers were quantified from whole section images with CellProfiler 63 , and random inserts were counted manually.
Whole organ images were taken on an SMZ1500 (Nikon) fluorescence dissection stereomicroscope equipped with a SPOT RT3 camera (Diagnostic Instruments) for an imaging area of 16 mm by 12 mm, with 3 s exposure for the liver and 4 s exposure for the heart, muscle, brain, and gonads. All images were acquired with a gain setting of 8 using the SPOT imaging software (Diagnostic Instruments, Sterling Heights, MI). Images for each organ were inverted and thresholded equally across animals.
Images were analyzed with ImageJ (NIH), CellProfiler 63 , and MATLAB (MathWorks).
Availability of software and scripts. Software is cited by primary literature and available on online repositories. All custom scripts used in the study will be readily provided upon request.
